Physician profile
Erick Bournigal
NPI 1275548547
$21,995.94
in general payments reported to CMS, 2019-2025
44 companies · $3,797 in 2025
The $3,797 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $268 · 2021: $655 · 2022: $8,442 · 2023: $3,447 · 2024: $4,215 · 2025: $3,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $810 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,420.57 |
| Consulting Fee | $810.00 |
| Education | $228.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $6,155.32 | 2019-2023 | Krystexxa |
| Abbvie INC. | $2,562.32 | 2019-2025 | Vraylar, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,038.81 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,882.54 | 2019-2025 | Krystexxa, Evenity, Prolia |
| Ucb, INC. | $1,542.52 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $1,279.38 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,067.55 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $759.52 | 2022-2025 | Saphnelo |
| Pfizer INC. | $734.68 | 2019-2025 | |
| Radius Health, INC. | $471.13 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $419.24 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $314.63 | 2020-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $262.32 | 2019-2025 | |
| Cardinal Health 110 LLC | $253.60 | 2024 | |
| Genentech USA, INC. | $253.18 | 2019-2025 | Actemra |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Bournigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.